The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease

Summary

The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain.

Timeline

Start

2007-06

Primary completion

2008-06

Completion

2008-10

Drugs

Indications